

# **Impact of Pre-Analytic Variation on Tissue Analysis: Issues & Practical Applications**

**Angelo M. De Marzo, MD, PhD - JHU**

**Samson Fine MD -MSKCC**

**Bruce J. Trock PhD - JHU**

# **Development of Standard Operating Procedures for Inter-SPORE Prostate Biomarker Study**

- **Handling of fluid specimens**
  - Blood, serum, plasma, etc
  
- **Handling of tissues**
  - Prostate needle biopsies
  - Radical prostatectomies

# **SPECIMEN HANDLING PRIOR TO PROCESSING**

- **SPECIMEN PRE-FIXATION**

- Time of anoxia prior to placement in fixative or freezing tissue for frozen biopsies (should be immediate by person taking the biopsies)
- Marking of biopsies with dye, such as safranin

- **SPECIMEN FIXATION**

- Type of Fixative: unless snap freezing specimens, usually 10% neutral buffered formalin, which is actually 4% formaldehyde
- Temperature of Fixation: usually room temperature
- pH and Osmolality of Fixation: controlled using neutral buffered formalin
- Volume of fixative

# TISSUE PROCESSING

- **POSTFIXATION**
  - Time of post-fixation (if any)
  - Chemical makeup of post-fixation
  - Temperature of post-fixation
  - Vendor of fixative
- **DEHYDRATION**
  - Time and number of steps
  - Chemical makeup of dehydration (i.e. 70 %, 80%, 95% ethanol)
  - Other non-ethanol chemicals (i.e. eosin, "pen-fix")
  - Temperature of each step
  - Vendor of chemicals
- **CLEARING**
  - Time and number of steps
  - Chemical makeup of clearing agent (most use xylene, but some use )
  - Other non-ethanol chemicals (i.e. eosin )
  - Temperature of each step
  - Vendor of chemicals
- **INFILTRATION**
  - Type of paraffin (there are several types)
  - Time, number of steps in paraffin
  - Temperature of paraffin

# **SPECIMEN HANDLING AFTER PROCESSING**


- **TISSUE SECTIONING**

- Thickness of sections
- Water bath temperature
- Presence of chemical in water bath (i.e. ammonia)
- Time and temperature of slide drying
- Time and temperature of baking slides (if done at this point)

- **SLIDE STORAGE**

- Temperature of slide storage
- Humidity of slide storage
- Oxygen levels
- Duration of slide storage under given conditions

# PTEN INTENSITY



# Rationale for Study

- Inter-SPORE Prostate Biomarker Study (IPBS)
- Issues regarding standard processing
- Prior studies in prostatic tissue have suggested that variability of tissue fixation and/or processing may affect biomarker interpretation
- **Quantify these variations and their potential impact on biomarker testing and analysis**

# Study Design

- **Prostate needle biopsies**

- Immediate fixation
- Primary tissue to be used in IPBS Prospective arm

- **Biomarkers**


- p27
- AMACR
- Ki-67
- 34 $\beta$ E12

**IMMUNOHISTOCHEMISTRY**

- Loss/gain in chromosome 8

**FISH**

# Effects of Tissue Processing Techniques on Biomarker Analysis for Prostate Cancer Specimens: An Inter-SPORE Study



# **Effects of Tissue Processing Techniques on Biomarker Analysis for Prostate Cancer Specimens: An Inter-SPORE Study**

**DATA FOR EACH  
MARKER IS  
ANALYZED PER SITE**



**IF SIGNIFICANT  
DIFFERENCES  
ARE DETECTED  
MARKERS ARE  
ANALYZED BY  
PROCESSING SCHEDULE  
VARIABLES**

# Study Participants


- BCM - Gustavo Ayala
- DFCI – Mark Rubin (\*)
- FHCRC – Larry True
- JHU – Angelo DeMarzo; Bruce Trock (\*)
- MAYO – Robert Jenkins; John Cheville (\*)
- MDACC – Patricia Troncoso
- MSKCC - Samson Fine; Victor Reuter (\*)
- NWU – Ximing Yang
- UCLA - Jonathan Said
- UCSF – Jeff Simko
- UMICH - Rajal Shah (\*)

# Needle Biopsy Tissue Processing Protocols

	Condition	Harvard/DFCI		FHCRC/U Wash		JHU		Umich		MDACC		Mayo Clinic		MSKCC	
		Time	Temp	Time	Temp	Time	Temp	Time	Temp	Time	Temp	Time	Temp	Time	Temp
Post-Fixation	10% Formalin	-	-	-	-	2	40	20	37	-	-	20	?	30	40
	10% Formalin	-	-	-	-	2	40	20	37	30	RT	-	-	30	40
	Penfix	-	-	10	37	-	-	-	-	-	-	-	-	-	-
	10% formalin in 95% eto	-	-	-	-	-	-	-	-	30	RT	-	-	-	-
Dehydration	70% ethanol	5	RT	-	-	2	40	20	37	30	RT	-	-	20	40
	70% ethanol	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	80% ethanol	15	RT	-	-	-	-	20	37	-	-	2	?	-	-
	80% ethanol	15	RT	-	-	-	-	-	-	-	-	5	?	-	-
	95% ethanol	15	RT	10	37	2	40	30	37	30	RT	-	-	10	40
	95% ethanol	15	RT	10	37	2	40	30	37	-	-	5	?	20	40
	100% ethanol	15	RT	10	37	2	40	35	37	30	RT	5	?	10	40
	100% ethanol	15	RT	10	37	-	-	35	37	30	RT	15	?	10	40
	100% ethanol	-	-	-	-	-	-	-	-	30	RT	-	-	20	40
	100% etoh/ 17% eosin	-	-	-	-	2	40	-	-	-	-	-	-	-	-
50% etoh/ 50% Xylene	-	-	-	-	5	40	-	-	-	-	-	-	-	-	
Clearing	Xylene	15	RT	10	37	2	40	35	37	30	RT	5	?	15	40
	Xylene	15	RT	10	37	2	40	40	37	30	RT	5	?	15	40
	Xylene	20	RT	10	37	-	-	-	-	-	-	-	-	-	-
Infiltration	Paraffin	20	RT	10	58	2	60	15	60	30	60	30	?	15	60
	Paraffin	20	RT	10	58	2	60	25	60	30	60	2	?	15	60
	Paraffin	-	-	10	58	5	60	25	60	30	60	-	-	20	60
	Paraffin	-	-	-	-	5	60	15	60	-	-	-	-	-	-
Total Time (minutes)		185		110		37		365		360		94		230	

1. p27 is a cell cycle inhibitor expressed in the secretory cells of normal prostatic glands
2. Reduced p27 staining has been proposed as a prognostic biomarker in prostate cancer
3. Shown by DeMarzo and Rubin to be artifactually decreased in RP specimens with brief fixation times

## Percentage of cases with p27 staining intensity = 3 to 4




Overall Staining Intensity: mean=3.5, median=4  
 No significant difference among SPOREs, p=0.105

**1. 34 $\beta$ E12 is an monoclonal antibody against high molecular weight CK expressed in basal cells of normal prostatic glands**

**2. Although unlikely to have prognostic value, 34 $\beta$ E12 is an important diagnostic marker with its absence denoting loss of basal cells, a cardinal feature of prostate cancer**


## Percentage of cases with 34 $\beta$ E12 staining intensity = 3



\* Significant difference in mean staining intensity (normals): UCSF=3.0, JHU=2.5, p=0.0009 (overall mean=2.91, median=3.0) (all normal sections had diffuse staining)

- 1. AMACR is an enzyme involved in  $\beta$ -oxidation of dietary branched-chain fatty acids which have been associated with an increased risk of prostate cancer**
- 2. Elevated levels of AMACR RNA and protein have been implicated as biomarkers for prostate cancer and have been shown to have both diagnostic and prognostic value**


## Percentage of tumors with AMACR staining intensity = 3 to 4



\* Significant difference in mean staining intensity among SPOREs: MDA=2.7, UMICH=2.8, UCSF=4.0,  $p=0.0002$  (overall mean=3.3, median=3.0)

- 1. Are these differences due to tissue processing variability or the underlying biologic potential of the tumors studied?**
- 2. While nearly all (94/98) cases studied were Gleason score 3+3=6, volume/density of tumor, stage and grade post-therapy and biologic outcome were not controlled**


## Percentage of tumors with AMACR staining intensity = 4



\* Significant difference in mean staining intensity among SPOREs: MDA=2.7, UMICH=2.8, UCSF=4.0,  $p=0.0002$  (overall mean=3.3, median=3.0)

1. Ki-67 is a nuclear proliferation antigen
2. Quantification of Ki-67 antigen using IHC has been shown to provide an estimation of growth fraction
3. Numerous studies have associated Ki-67 with tumor grade/stage, recurrence and metastasis post-therapy and cause specific death from prostate cancer

## Mean In(%) tumor cells staining for Ki-67




\* Significant difference in ln(percentage) of cells staining among SPOREs: DFCI 2.6 (19.2%), JHU 1.0 (3.5%),  $p=0.0002$  (overall mean=7.5, median=5.8)

1. 8p22 loss & 8q24 gain are common alterations in prostate CA

2. Losses/gains of chr. 8 are implicated in tumorigenesis, advanced, metastatic, and androgen-independent disease

3. Quantification of signal is dependent on having intact interphase nuclei

Frequency of 8p22 loss - 8q24 normal, 8p22 loss - 8q24 gain, or gain entire chromosome 8



# Results

- Significant associations:
  - p27 staining intensity: ↓ with ↑ minimum fixation time (p=0.039); ↑ with ↑ dehydration time (p=0.011)
  - 34βE12 staining intensity: ↑ with ↑ maximum fixation time (p=0.015)
  - AMACR staining intensity : ↓ with ↑ minimum fixation time (p=0.001); ↑ with ↑ dehydration time (p=0.0002)
  - Ki-67 In(%) cells staining: ↓ with ↑ infiltration temperature (p=0.035)

# Conclusions

- As a predecessor to the IPBS, the current study demonstrates the collaborative potential of the Prostate SPORE sites to conduct biomarker studies
- Pilot data for p27 and 34 $\beta$ E12 in needle biopsies suggest that near-equivalent labeling of normal prostatic tissue is possible across SPORE sites
- Variability in results seen with biomarkers likely reflects both processing and tumor biology

# Lessons Learned – Phase I


- Pathologists from the 11 Prostate SPORE sites can work together to accomplish projects of global importance
- Significant variability exists in processing schedules
- Good correlation may be achieved for some markers of nl prostate
- Interpretable FISH signals could be detected across SPORE sites
- Significant variation exists for tumor markers: processing v. tumor heterogeneity
- Associations between specific processing/sectioning steps and biomarker results may be identified

## **Next Steps (Phase II) – Control of Biological Variability**

- Take multiple biopsies from human prostate cancer xenograft tumors, fix immediately under identical conditions and send specimens to various sites for processing; blocks sent to MSKCC, sections cut and sent out to labs for biomarker testing.
- Take multiple biopsies from a single RP case and fix immediately under identical conditions and do the same.


## **Next Steps (Phase II) – Control of Biological Variability**


- N = 3 xenograft tumors already biopsied, fixed, sent to 11 institutions for their processing, processed and awaiting cutting at MSKCC.
- N=15 RRPs already biopsied at JHU, sent and processed and blocks being sent to MSKCC.
- Creation of a “processing array.



# *The TMAJ Software Project*

<http://tmaj.pathology.jhmi.edu>





# What is *TMAJ*?

---

- *TMA-J* is a set of open source software tools and backend database structure to facilitate management and analysis of tissue microarrays and associated pathology and image data

#599 Session, ArraySlideID#477 (TMA#358, Cut#2, Stain-PTEN)

Options

ScoredImageID	Primary_Histologic_Type	Secondary_Histologic_Type	Percent_Positive	Percent_Strong	Nc
	Normal Prostatic Epithelium		100	80	


Type: **Prostate -- Normal/Other**

Draw Save Link Info Large

Back Up Next  
Down

X: 12 Y: 1

Accept



Projects

Open Session

Recent Sessions

- #5 Session,
- #7 Session,
- #46 Session

All Sessions

- My Project
- Shared S
- Publishe

# Image Application: Filtering

- The table shows information about every image (identified by x and y)

#3 Session, ArraySlideID#3 (TMA#18, Cut#3)

Remove

X	Y	Control	Primary_Histolog
9	17	tonsil	Not Specified
10	17		Normal Prostatic Epitheli
11	17		Normal Prostatic Epitheli
12	17		Normal Prostatic Epitheli
13	17		Normal Prostatic Epitheli
14	17		Prostatic Adenocarcinom
15	17		Normal Prostatic Epitheli
16	17		Normal Prostatic Epitheli
17	17		Normal Prostatic Epitheli
18	17	vas	Not Specified
19	17	vas	Normal Prostatic Stroma
20	17	brain	Not Specified
1	18		Normal Prostatic Epitheli
2	18		Normal Prostatic Epitheli
3	18		Normal Prostatic Epitheli
4	18		Normal Prostatic Epitheli

**399 records**

#350 Session, ArraySlideID#200 (TMA#33, Cut#35, stain-MCM2/)

	0	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20
1																					
2																					
3																					
4																					
5																					
6																					
7																					
8																					
9																					
10																					
11																					
12																					
13																					
14																					
15																					
16																					
17																					
18																					
19																					
20																					

Clear Data Thumbs Mark

# Images Application: Viewing 2

#41 Session, ArraySlideID#26 (TMA#18, Cut#22, stain-TFF)

0	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20
1																				
2																				
3																				

#41 Session, ArraySlideID#26 (TMA#18, Cut#22, stain-TFF)


Options

ArrayImageID	Primary_Histologic_Type	Notes
14026	Prostatic Adenocarcinoma, Gleason 3, Non Cribriform	

Type: **Prostate -- Carcinoma**

Back Up Next  Accept  
Down

Save Undo Link Info Large



#42 Session, ArraySlideID#27 (TMA#18, Cut#23, stain-p63)

0	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20
1																				
2																				
3																				

#42 Session, ArraySlideID#27 (TMA#18, Cut#23, stain-p63)

Options

ArrayImageID	Primary_Histologic_Type	Notes
14408	Prostatic Adenocarcinoma, Gleason 3, Non Cribriform	


Type: **Prostate -- Carcinoma**

Back Up Next  Accept  
Down

Save Undo Link Info Large




# Publishing TMA Images and Scoring Data Over the Internet



---


- Roughly modeled after Stanford Microarray Database
  - Concept:
    - Once a study is published by a journal, all TMA diagnoses, image, scoring and non-protected clinical data can be “published” as supplemental data to the Internet for public online viewing or down loading
    - TMAJ Images now linked to “Proteinpedia” database
- (<http://humanproteinpedia.org>) by Akhilesh Pandey, MD PhD.



# For More Information

---

- <http://tmaj.pathology.jhmi.edu>
- To see published images
  - login to tmaj as a guest and then click the Images button.
    - Username: guest
    - Password: guest



# Institutions Using TMAJ

---

- Johns Hopkins University
- Harvard Dana Farber Cancer Institute
- Cleveland Clinic
- University of Texas Southwestern
- Vanderbilt University